Navigation Links
Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Date:11/9/2009

, 2008 to $174.2 million as of September 26, 2009 and further reduced to $149.5 million as of today.

Fourth quarter fiscal 2009 revenues totaled $402.8 million, a decrease of 9.0% when compared to revenues of $442.5 million in the fourth quarter of fiscal 2008. The decrease was primarily attributable to the year-over-year decline in sales of Selenia systems. We believe this decline continues to be due, in large part, to the current economic environment and the resulting delays and reductions in hospital capital spending as compared to the same period in the prior fiscal year. Also contributing to this decline, to a lesser extent, was the year-over-year decline in Skeletal Health product revenues of $5.9 million. These declines were partially offset by: (i) growth in Diagnostics and GYN Surgical product sales of $14.7 million as compared to the fourth quarter of fiscal 2008, including an increase of $3.7 million from Third Wave, which we acquired in July 2008; and (ii) an $8.7 million, or 17.9%, increase in service and other revenues primarily related to our increased installed base of Selenia full field digital mammography systems.

For the fourth quarter of fiscal 2009, Hologic reported net income of $34.9 million, or $0.13 per diluted share, compared with a net loss of $144.4 million, or $0.56 per diluted share, in the fourth quarter of fiscal 2008. Included in fourth quarter fiscal 2009 results were: (i) a charge of $46.3 million attributable to the amortization of intangibles relating to the Cytyc merger and the Third Wave acquisition; (ii) a full quarter of costs and expenses from Third Wave of $13.8 million (excluding amortization expense); and (iii) operating charges of $2.0 million related to the closure of the Company's organic photoconductor drum coatings manufacturing operations in Shanghai, which the Company had acquired as part of its acquisition of AEG in fiscal 2006. Included in the fourth quarter of fiscal 2008 results
'/>"/>

SOURCE Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014  As the Medical Affairs, role has become ... this area are exploring methods to develop strong capabilities ... Consortium at Best Practices, LLC is designed to give ... the key challenges they face. The consortium will provide ... virtual roundtable discussions where leaders discuss key findings from ...
(Date:8/22/2014)... Ohio , Aug. 22, 2014 MC Medical, ... Inc. (MID), a Columbus, OH medical ... distribute the FloShield laparoscopic and robotic visualization system in ... be approved for sale in Japan ... a long-time experience and an extensive product portfolio in endoscopic ...
(Date:8/22/2014)... Aug. 22, 2014  Research presented at the 29 th ... developed by Hera Therapeutics Inc. combats three types of human ... cervical cancer. When tested in several cultured human ... HPV-11 cells, according to Louise T. Chow , Ph.D. ... at the Seattle conference. The National ...
Breaking Medicine Technology:Best Practices' Medical Affairs Consortium Survey Has Achieved Strong Participation 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... KALAMAZOO, Mich., Sept. 9 Global Pharmaceutical Services ... the worldwide pharmaceutical and biotechnology industry announces a new clinical ... has entered into an exclusive partnership with Abridge Clinical Research ... India. "We are delighted in working with such an experienced ...
... , IRVINE, Calif., Sept. 8 ... U.S. Food and Drug Administration (FDA) has approved Bepreve(TM) (bepotastine besilate ... ocular itching associated with allergic conjunctivitis in patients two years of ... new, safe and effective way to treat the itching caused by ...
Cached Medicine Technology:Life Sciences Company Opens Clinical Trial Bridge to India 2ISTA Pharmaceuticals' Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies 2ISTA Pharmaceuticals' Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies 3ISTA Pharmaceuticals' Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies 4ISTA Pharmaceuticals' Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies 5
(Date:8/22/2014)... Penn Medicine team has found that targeted automated ... tract infections in hospital patients with urinary catheters. ... was simplified, the rate of improvement dramatically increased. ... patients need urinary catheters in the first place ... for catheters that have not been removed within ...
(Date:8/22/2014)... Natural Clear Vision , a how-to guide ... vision from legally blind to perfect 20/20 vision has caught ... , “There is a huge portion of the population today ... most people just think that’s the way it will always ... be pretty risky at times,” reports Michaels. “This program is ...
(Date:8/22/2014)... Epidermal growth factor receptor (EGFR) mutations found in the ... advanced non-small cell lung cancer (NSCLC) patients correlates well ... , EGFR tyrosine kinase inhibitor (TKI) therapy is approved ... but the standard for determining mutation status is with ... limited or not available. A more abundant and less ...
(Date:8/22/2014)... York, New York (PRWEB) August 22, 2014 ... continue to be filed in U.S. courts on ... events due to their use of prescription low ... court documents, a new claim was filed against ... man who allegedly suffered life-threatening heart issues due ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- An intensive effort ... to an animal shelter in Florida and euthanized, a new ... enough cats to slow their intake into animal control," Dr. ... of Florida College of Veterinary Medicine, said in a university ... there wasn,t making a big impact," she explained, "so we ...
Breaking Medicine News(10 mins):Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 3Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Neutering Project Curbed Feral Cat Population 2
... Pharmacopeia,(Nasdaq: PCOP ), an innovator in ... today announced that it has licensed from,Bristol-Myers Squibb ... modulator,(SARM) program, including a lead compound in Phase ... non-steroidal selective androgen,receptor modulator, or SARM, which was ...
... Ill. A study published in the October ... (JCSM) finds that modafinil is well-tolerated in the treatment ... wakefulness such as shift work sleep disorder, obstructive sleep ... or sleep parameters. , The study, authored by Thomas ...
... 15 With school schedules now routine and,the initial ... again",sighs. This might be a good time to re-evaluate ... http://www.newscom.com/cgi-bin/prnh/20071015/NYFNSL01 ) The following are suggestions ... and snacks for greater nutritional impact. Add a,handful of ...
... - ,Real Women, Real Pain, Campaign Highlights ... in Women Around the World Today, the International ... the Global Year Against Pain in Women to draw ... and the need for more,effective care. Lack of awareness ...
... A new study by Rhode Island Hospital and Brown University ... surgery did not receive the initial psychiatric clearance for the ... of decisions to clear candidates for surgery, and the largest ... and detail the reasons for exclusion. It was published in ...
... Attention-deficit/hyperactivity disorder (ADHD), a state of serious impairments in ... many labels for one of the most prevalent conditions ... partly persists into adulthood. ADHD is conservatively estimated to ... 1998), but more permissive criteria yield estimates of up ...
Cached Medicine News:Health News:Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb 2Health News:Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb 3Health News:Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb 4Health News:Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb 5Health News:Study: Modafinil is effective in treating excessive sleepiness 2Health News:Fresh, Tasty - Healthy - Lunch and Snack Ideas 2Health News:International Association for the Study of Pain (IASP) Declares the Global Year Against Pain in Women 2Health News:International Association for the Study of Pain (IASP) Declares the Global Year Against Pain in Women 3Health News:1 in 5 bariatric surgery candidates not psychologically cleared for surgery 2Health News:Computerized training of working memory is a promising therapeutic strategy in ADHD 2Health News:Computerized training of working memory is a promising therapeutic strategy in ADHD 3
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
... The iCycler iQ real-time PCR detection system ... fits into place directly above the thermal ... excitation/emission wavelengths available, facilitating the greatest array ... part of the iCycler iQ system, the ...
... PRISM 7900HT Sequence Detection System is ... detects and quantitates nucleic acid sequences. ... plate capability make the 7900HT system ... requirements of todays drug discovery process. ...
Chemically Resistant Sealing Mat for 384ch, Square Well Available Sterile...
Medicine Products: